Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

8 trials in Phase 3/4

Results Transparency

69%

9 of 13 completed trials have results

Key Signals

1 recruiting9 with results

Enrollment Performance

Analytics

Phase 3
8(57.1%)
Phase 2
6(42.9%)
14Total
Phase 3(8)
Phase 2(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials
NCT06542497Phase 3Completed

Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

Role: lead

NCT06349759Phase 3Completed

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

Role: lead

NCT05646719Phase 3Completed

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

Role: lead

NCT04638660Phase 3Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

Role: lead

NCT04675151Phase 2Completed

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

Role: lead

NCT07140783Phase 3Recruiting

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

Role: lead

NCT04004507Phase 2Completed

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

Role: lead

NCT03960866Phase 2Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

Role: lead

NCT04620213Phase 3Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Role: lead

NCT05223478Phase 3Completed

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

Role: lead

NCT05134974Phase 3Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

Role: lead

NCT04024891Phase 2Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Role: lead

NCT04692688Phase 2Completed

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Role: lead

NCT01703559Phase 2Completed

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

Role: lead

All 14 trials loaded